Table 1 SARP III Pediatric sample features compared by sex
From: Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma
|  | Males (n = 116) | Females (n = 71) | P value | |
Age, years, mean (± sd) | 11.3 (± 2.7) | 11.8 (± 3.1) | 0.21 | |
Age of asthma diagnosis | 3.1 (± 2.7) | 3.1 (± 2.7) | 0.90 | |
Years since onset of asthma symptoms (asthma duration) | 9.0 (± 3.2) | 9.4(± 3.5) | 0.50 | |
BMI percentile | 76.9 (± 26.5) | 73.5 (± 27.1) | 0.40 | |
Race/ethnicity, n (%) | ||||
 White non-Hispanic | 28 (24) | 26 (37) | 0.26 | |
 African American non-Hispanic | 51 (44) | 26 (37) | ||
 Hispanic | 17 (15) | 11 (15) | ||
 Other | 20 (17) | 8 (11) | ||
Asthma severity, n (%) | ||||
 Severe | 66 (57) | 44 (62) | 0.49 | |
 Not severe | 50 (43) | 27 (38) | ||
Systemic Corticosteroid Treatment (current) | 11 (9) | 5 (7) | 0.56 | |
Systemic Corticosteroid Treatment (past 3 mos) | 7 (6) | 3 (4) | 0.59 | |
 High-Dose Inhaled Corticosteroids | 82 (71) | 50 (70) | 0.97 | |
 Low-Medium-Dose Inhaled Corticosteroids | 23 (20) | 14 (20) | 0.99 | |
Montelukast (during last 12Â months) n(%) | 71 (60) | 54 (76) | 0.03 | |
Long-acting beta agonist | 86 (74) | 49 (69) | 0.45 | |
Atopic sensitization | Â | Â | Â | |
At Least One Positive Specific IgE (of 15 tests) | 106 (93) | 64 (91) | 0.70 | |
Number of Positive Specific IgEs (of 15 tests). Mean (± sd) | 7.0 (4.3) | 7.0 (4.9) | 0.95 | |
History of atopic dermatitis. n(%) | 74 (64) | 44 (62) | 0.80 | |
Tanner stage, n (%) | Males | Females | Â | |
Pubic hair | Breast development | Pubic hair | Â | |
 I | 67 (58) | 14 (20) | 24 (34) |  |
 II | 17 (15) | 18 (25) | 13 (18) |  |
 III | 8 (7) | 16 (23) | 8 (11) |  |
 IV | 7 (6) | 9 (13) | 13 (18) |  |
 V | 17 (15) | 14 (20) | 13 (18) |  |